A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity

Contraception

Volumn 56, Issue 1, 1997, Pages 23-30

  Rossmanith, Winfried G ^a   Steffens, Doris ^b   Schramm, Georg ^b  

^a UNIVERSITY OF ULM   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Cervical mucus; Endometrium; Endosonography; Follicle like structures; Gonadotropins; Oral contraception

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; EVE 20; FOLLITROPIN; LUTEINIZING HORMONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOGRAPHY; ENDOMETRIUM; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MULTICENTER STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVULATION INHIBITION; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX MUCUS;

BIOLOGY; CERVICAL MUCUS; CERVIX; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, FEMALE--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, PROGESTIN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE METHODS--PHARMACODYNAMICS; CONTRACEPTIVE MODE OF ACTION; DESOGESTREL--ADMINISTRACTION AND DOSAGE; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; ENDOMETRIAL EFFECTS; ENDOMETRIUM; ETHINYL ESTRADIOL--ADMINISTRACTION AND DOSAGE; EUROPE; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; GERMANY; GONADOTROPINS; GONADOTROPINS, PITUITARY; HORMONES; NORETHINDRONE--ADMINISTRACTION AND DOSAGE; ORAL CONTRACEPTIVES, LOW-DOSE--PHARMACODYNAMICS; ORAL CONTRACEPTIVES--PHARMACODYNAMICS; OVARIAN EFFECTS; OVARY; OVULATION SUPPRESSION; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; UROGENITAL SYSTEM; UTERUS; WESTERN EUROPE;

ADULT; CERVIX MUCUS; COHORT STUDIES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; NORETHINDRONE; OVARY; PROGESTERONE; STEROIDS;

EID: 0030886742     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00070-X     Document Type: Article

References (25)

1. Mishell DR Jr. Contraception. In: DeGroot L, ed. Endocrinology, Volume 3. Philadelphia: Saunders, 1995: 2140-68.
2. Fitzgerald C, Feichtinger W, Spona J, et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contraception 1994;10:5-18.
3. Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994;83:29-34.
4. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583-90.
5. Caillouette JC, Koehler AL. Phasic contraceptives and functional ovarian cysts. Am J Obstet Gynecol 1987; 156:1538-42.
6. Young RL, Snabes MC, Frank ML, Reilly M. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. Am J Obstet Gynecol 1992; 167:678-82.
7. Van der Does J, Exalto N, Dieben T, Coelingh Bennink H. Ovarian activity suppression by two different low-dose triphasic oral contraceptives. Contraception 1995; 52:357-61.
8. Queenan JT, O'Brian GD, Bains LM, et al. Ultrasound scanning of ovaries to detect ovulation. Fertil Steril 1980;34:99-105.
9. Tayob Y, Robinson G, Adams J, et al. Ultrasound appearance of the ovaries during the pill-free interval. Br J Fam Planning 1990;16:94-6.
10. Broome M, Clayton J, Fotherby K. Enlarged follicles in women using oral contraceptives. Contraception 1995; 52:13-6.
11. Mogavero G, Sheth S, Hamper UM. Endovaginal sonography of the nongravid uterus. Radiographics 1993;13: 969-81.
12. Insler V, Melmed H, Ser D, Lunenfeld B. The cervical score. Int J Gynecol Obstet 1972;10:223.
13. Rossmanith WG, Wirth U, Benz R, Wolf AS. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease. Gynecol Endocrinol 1989;3:21-34.
14. Wenzl HC, Bennink H, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17-beta-estradiol. Fertil Steril 1993;60:616-9.
15. Killick SR, Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycles. Fertil Steril 1987;48:409-13.
16. Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol 1989;161:1159-62.
17. Kafrissen ME. A norgestimate-containing oral contraceptive: review of clinical studies. Am J Obstet Gynecol 1992;167:1196-202.
18. Kekkonen R, Lahteenmaki P, Luukkainen T, Tuominen J. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Fertil Steril 1993;60:610-5.
19. Holt VL, Daling JR, McKnight B, et al. Functional ovarian cysts in relation to oral contraceptive use. Obstet Gynecol 1992;79:529-33.
20. Grimes DA, Hughes JM. Use of multiphasic oral contraceptives and hospitalization of women with functional ovarian cysts. Obstet Gynecol 1989;160: 523.
21. Brill K, Schnitker J, Albring M. Clinical experience with a modern low-dose gestodene-containing oral contraceptive in adolescents. Adv Contraception 1994;10: 237-47.
22. Van Dierendonck B, Ekwempu CC, Ladipo OA, Ulasi JN, Giwa-Osagie OF. A multicenter clinical trial in Nigeria with a low-dose oral contraceptive, Marvelon. Adv Contraception 1991;9:25-32.
23. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage 1993;8:98-114.
24. Fruzzetti F, Ricci C, Nicoletti I, Fioretti P. Clinical and metabolic effects of a triphasic pill containing gestodene. Contraception 1992;46:335-47.
25. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol. Br J Obstet Gynecol 1993;100:832-8.